Mutations in EGFR and early TP53 mutations involve in deregulating the cell cycle, evading cell death and facilitating tolerance of pervasive whole-genome doubling (WGD) and chromosomal instability (CIN), which results in early clonal selection with subsequent high intra-tumor heterogeneity. The gene discussed is EGFR; the disease is neoplasm.